Acceleron Pharma Current Ratio 2012-2021 | XLRN

Current and historical current ratio for Acceleron Pharma (XLRN) from 2012 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Acceleron Pharma current ratio for the three months ending June 30, 2021 was 12.07.
Acceleron Pharma Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.72B $0.06B 12.07
2021-03-31 $0.74B $0.05B 14.81
2020-12-31 $0.89B $0.06B 14.85
2020-09-30 $0.91B $0.04B 24.50
2020-06-30 $0.45B $0.04B 12.02
2020-03-31 $0.43B $0.03B 15.15
2019-12-31 $0.45B $0.03B 13.48
2019-09-30 $0.44B $0.03B 14.02
2019-06-30 $0.45B $0.03B 17.11
2019-03-31 $0.45B $0.02B 19.26
2018-12-31 $0.31B $0.02B 16.18
2018-09-30 $0.32B $0.02B 21.68
2018-06-30 $0.30B $0.02B 20.53
2018-03-31 $0.30B $0.01B 23.20
2017-12-31 $0.29B $0.02B 17.04
2017-09-30 $0.34B $0.02B 21.62
2017-06-30 $0.15B $0.01B 10.38
2017-03-31 $0.15B $0.02B 9.81
2016-12-31 $0.15B $0.02B 9.09
2016-09-30 $0.15B $0.02B 8.95
2016-06-30 $0.13B $0.01B 9.28
2016-03-31 $0.17B $0.02B 11.25
2015-12-31 $0.11B $0.01B 7.66
2015-09-30 $0.12B $0.01B 9.51
2015-06-30 $0.12B $0.01B 10.58
2015-03-31 $0.11B $0.01B 11.02
2014-12-31 $0.18B $0.01B 19.70
2014-09-30 $0.20B $0.01B 17.68
2014-06-30 $0.21B $0.02B 13.06
2014-03-31 $0.22B $0.01B 23.78
2013-12-31 $0.12B $0.03B 4.37
2013-09-30 $0.12B $0.02B 7.43
2013-06-30 $0.00B 0.00
2013-03-31 $0.00B 0.00
2012-12-31 $0.00B 0.00
2012-09-30 $0.00B 0.00
2011-12-31 $0.07B $0.02B 2.84
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.594B $0.093B
Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76